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• Institutional Review Board (IRB) exempt
• Retrospective electronic health record (EHR) based 
study of multiple ElderPlace clinic sites in Oregon.
• All patients meeting inclusion criteria were included
• Study population:
• Providence ElderPlace participants on routine 
opioids for chronic pain only (>6 months).
• Study period:
• March 1, 2020 – October 1, 2020
• Exclusion criteria:
• Palliative care Stage 2 and Stage 3
• Outcomes: 
• Primary: Trends in opioid prescribing using 
surrogate markers such as:
• Average MEDD
• Functional goals of therapy
• Alternative therapy offered/provided
• Informed consent
• ElderPlace protocol use
• Safety: Falls and opioid-related hospitalizations
Patient Population
• Total of 610 people were originally enrolled in the study. 
After screening, 168 patients were utilized to determine the 
clinical and safety outcomes.
• At baseline, patients were of average of geriatric age (≥65 
years old)
• Mean age was 76 years (range 57-97 years).
• Majority of patients were not of palliative care status.
• Opioid use prior to joining ElderPlace was 69.6% of the 
study population with majority of use being scheduled 
narcotics.
• The most used opioid medications were oxycodone and 
hydrocodone-acetaminophen followed by morphine. 
• Additional opioid medications used chronically were 
tramadol, codeine, fentanyl, hydromorphone, and 
methadone.
Outcomes
• The average morphine equivalent daily dose was 33.6 mg 
per day.
• 91, 53, 17 and 7 patients required <25 MEDD, 25-49 MEDD, 
50-119 MEDD, and ≥120 MEDD respectively.
• Only 41.7% of the patient population had defined functional 
goals.
• 95.8% of patients had alternative forms of pain 
management (non-controlled medications, topicals, physical 
therapy, acupuncture, etc.) in addition to opioids.
• 23 (13.7%) patients provided informed consent and 10 
followed the current ElderPlace protocol.
• Total of 78 falls occurred in 49 different patients. Of those 
patients 89.8% had 1-2 falls, 8.2% had 3-4 falls, & 2% had >5 
falls.
• Total of 67 hospitalizations occurred in 37 different patients-
- of those, only 18 were opioids related.
• Falls were more frequent in Palliative Care Stage 1 patients.
Study Limitations
• Retrospective, non-randomized study
• Risk of information bias since clinical outcomes determined 
via chart review
• Short study time frame
• Unable to assess compliance, efficacy of current therapy, 
and use of PRN medications
• Did not assess cause of falls 
• Specific goals were not defined to determine success
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• Providence ElderPlace in Oregon is the fifth-largest 
PACE program in the country that offers wraparound 
nursing home-eligible  medical and social services to 
over 1600 community-dwelling seniors who are 
medically frail with complex medication regimens. 
• Many elderly patients suffer from chronic non-
malignant pain which may affect their function and 
quality of life.  
• The Centers for Disease Control and Prevention (CDC) 
reports a 7.7% increase in drug overdoses and opioid 
deaths in the aging population from 2013 to 2014. 
• In 2015-2016 elderly adults obtained an annual 
average of 774 Morphine Milligram Equivalents 
(MME) of outpatient prescriptions for chronic & acute 
pain.
• Multiple comorbidities and age-related changes may 
affect distribution, metabolism, and elimination, 
older adults are at increased risk of adverse drug 
events and reactions.
• Physician prescribing practices has been shown to 
play an important role in high rates of prescription 
opioid use and misuse. 
• This study was performed to evaluate trends in opioid 
prescribing for chronic pain at Providence ElderPlace in 
Oregon.
• Overall, ElderPlace has high compliance at providing 
alternative therapy in addition to opioids for pain 
management, but minimal compliance with following the 
PACE guideline
• Low percentage of patients on opioids experienced falls or 
hospitalizations during the study period. No clear 
correlation between average MEDD and safety outcomes.
• Room for improvement includes determining clear 
functional goals in relation to pain and obtaining a signed 
material risk notice (which will enhance ElderPlace protocol 
use).
Purpose
• To determine trends in opioid prescribing for chronic 
pain in geriatric patients enrolled with Providence 
ElderPlace in Oregon
Methodology
• Discuss trends in opioid prescribing for chronic pain 
in geriatric patients at Providence ElderPlace
• Determine if opioids are being safely prescribed at 
Providence ElderPlace
• Identify potential gaps that can be addressed to 
improve opioid prescribing safety
Results
Characteristic (n=168)
Age, years, mean 76 (range 57-97)
Sex, female, No. (%) 127 (75.6)
Palliative Care, No. (%)
None 108 (64.3)
Stage 1 60 (35.7)
Pain History, No. (%)
Opioid use prior to enrollment 117 (69.6)
Scheduled 69 (59.0)
PRN 48 (41.0)
Active PRN opioid prescription 72 (42.9)
PRN = as needed
Health & Services
Outcome No. (%)
MEDD, mg/day, mean 33.6 (range 2.5-360)
Defined functional goals 70 (41.7)
Alternative therapy offered 161 (95.8)
Informed consent 23 (13.7)
Protocol followed 10 (6.0)












±Number of cases across 49 different people
♢Number of cases across 37 different people
*Opioid-related defined as altered mental status, fall, pain, or 
respiratory depression
+Number of cases across 12 different people







Graph 1. Opioid use
Non-CII: tramadol (5), codeine (1); Combo: morphine + tramadol (1) 
or oxycodone + methadone (3); Other: fentanyl oral (3) and patch (2), 
hydromorphone (1), and methadone (1)
Table 1. Patient baseline characteristics























Graph 2. Number of patients per MEDD by palliative stage class
Table 3. Falls and hospitalizationsGraph 3. Falls by average MEDD 
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